35 Although the primary endpoint of this trial failed to reach statistical significance (all-cause mortality or cardiovascular hospitalization), all-cause mortality alone was significantly lower in the carvedilol group than in the placebo group (116 [12%] versus 151 [15%]; 95% confidence interval: 0·77 [0·60–0·98], P = 0.03) and confirmed data from other studies.
1
—
—